Related Experiment Video
Updated: Jul 19, 2025

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
Published on: November 10, 2023
Coronavirus disease 2019 and cardiovascular disease
Jenn-Yeu Song1,2,3, Jian-You Huang3,4, Yi-Chiung Hsu2
1Division of Cardiovascular Surgery, Department of Surgery, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei, Taiwan.
Insights
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can cause myocardial damage in COVID-19 patients. Understanding these cardiovascular effects is crucial for effective treatment and reducing mortality risks.
Area of Science:
- Cardiology
- Virology
- Pathophysiology
Background:
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19).
- Cardiovascular diseases (CVDs) are known risk factors for increased mortality.
- COVID-19 has demonstrated significant cardiovascular manifestations and adverse prognostic impacts.
Purpose of the Study:
- To review existing evidence on the mechanisms of myocardial damage in COVID-19 patients.
- To enhance understanding of SARS-CoV-2-induced cardiovascular damage.
- To inform prompt and efficient treatment strategies for COVID-19 patients with cardiovascular involvement.
Main Methods:
- Literature review of existing evidence.
- Analysis of potential mechanisms of myocardial injury.
- Overview of cardiovascular manifestations and complications in COVID-19.
Main Results:
- SARS-CoV-2 infection can lead to acute myocardial injury, potentially mediated by the angiotensin-converting enzyme 2 receptor.
- COVID-19 can exacerbate existing heart failure through increased oxygen demand, myocarditis, stress cardiomyopathy, pulmonary hypertension, and venous thrombosis.
- Severe COVID-19 may result in cardiogenic shock and acute systolic heart failure.
Conclusions:
- Comprehensive knowledge of SARS-CoV-2 cardiovascular damage mechanisms is vital for reducing mortality.
- Treatment options for refractory circulatory support include extracorporeal membrane oxygenation (ECMO) and left ventricular assist devices (LVADs).
- Continuous monitoring of SARS-CoV-2 evolution and transmissibility is essential for future cardiovascular disease surveillance.
Abstract:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus behind the coronavirus disease 2019 (COVID-19) pandemic, is a type of RNA virus that is nonsegmented. Cardiovascular diseases (CVDs) increase the mortality risk of patients. In this review article, we overview the existing evidence regarding the potential mechanisms of myocardial damage in coronavirus disease 2019 (COVID-19) patients. Having a comprehensive knowledge of the cardiovascular damage caused by SARS-CoV-2 and its underlying mechanisms is essential for providing prompt and efficient treatment, ultimately leading to a reduction in mortality rates. Severe COVID-19 causes acute respiratory distress syndrome and shock in patients. In addition, awareness regarding COVID-19 cardiovascular manifestations has increased, including the adverse impact on prognosis with cardiovascular involvement. Angiotensin-converting enzyme 2 receptor may play a role in acute myocardial injury caused by SARS-CoV-2 infection. COVID-19 patients experiencing heart failure may have their condition exacerbated by various contributing factors and mechanisms. Increased oxygen demand, myocarditis, stress cardiomyopathy, elevated pulmonary pressures, and venous thrombosis are potential health issues. The combination of these factors may lead to COVID-19-related cardiogenic shock, resulting in acute systolic heart failure. Extracorporeal membrane oxygenation (ECMO) and left ventricular assist devices (LVADs) are treatment options when inotropic support fails for effective circulatory support. To ensure effective COVID-19-related cardiovascular disease (CVD) surveillance, it is crucial to closely monitor the future host adaptation, viral evolution, and transmissibility of SARS-CoV-2, given the virus's pandemic potential.
More Related Videos
08:41Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
13:07Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
Published on: January 15, 2022
Related Concept Videos
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Coronary Artery Disease I: Introduction
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease III: Clinical Manifestations
Cardiovascular Drugs: Classification based on Therapeutic Indications
Coronary Artery Disease IV: Preventive Measures